 |
Video: What is a Stock Split?
|
 |
| Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Co. develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. According to our SNSE split history records, Sensei Biotherapeutics has had 1 split. | |
 |

Sensei Biotherapeutics (SNSE) has 1 split in our SNSE split history database. The split for SNSE took place on June 17, 2025. This was a 1 for 20 reverse split, meaning for each 20 shares of SNSE owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.
When a company such as Sensei Biotherapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the SNSE split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Sensei Biotherapeutics shares, starting with a $10,000 purchase of SNSE, presented on a split-history-adjusted basis factoring in the complete SNSE split history.

Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
02/05/2021 |
|
| End date: |
02/13/2026 |
|
| Start price/share: |
$449.80 |
|
| End price/share: |
$9.09 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-97.98% |
|
| Average Annual Total Return: |
-54.00% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$202.06 |
|
| Years: |
5.02 |
|
|
 |
| Date |
Ratio |
| 06/17/2025 | 1 for 20 |
|
 |